Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06760130

Retrospective Evaluation of Infections After Delivery

In general, transabdominal and transvaginal ultrasound represent the first imaging method in the study of suspected postpartum infections because of its good sensitivity, low cost, and high safety for patients (in fact, it allows the patient to be studied at the bedside, even in clinically unstable patients, it is well tolerated by patients, and it has no risks). CT has an excellent sensitivity in the diagnosis of postpartum infections, however, it has some drawbacks: it is not an examination that can be performed in clinically unstable patients, it cannot be performed at the patient's bedside, it has high costs, and it involves the administration of a significant dose of radiation . There are conflicting data in the literature regarding which examination is most useful for the diagnosis/management of infections in postpartum. Therefore, the investigators want to evaluate whether ultrasound alone, compared with management with combined ultrasound and CT scan, is a useful and sufficient diagnostic tool for the diagnosis and management of postpartum infectious complications.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, 40138, Italy

About this study

Cases of infection recorded as a result of these parts will be reviewed. Laboratory tests and clinical data of these will be reviewed. Instrumental, ultrasound and CT images taken in the postpartum for diagnostic confirmation and subsequent follow-up will also be reviewed.

For each patient, information will be collected on:

  • Age, weight, height
  • Previous pregnancies and their outcome
  • Pregnancy that arose spontaneously or through Medically Assisted Procreation techniques
  • Conditions concomitant or complicating pregnancy
  • Pregnancy outcome (spontaneous delivery or cesarean section)
  • Laboratory tests
  • Clinical data collected during hospitalization (vital parameters, symptoms, any medications administered)
  • Radiologic (CT) or ultrasound (transabdominal and/or transvaginal) investigations performed during the hospital stay, in continuation-iter or in a subsequent hospitalization: name and model (and probe, for ultrasound examinations) of the equipment used will be specified for each examination performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 18 years or older
  • Diagnosis of postpartum infection (within 30 days after delivery).

Clinical diagnosis is established by the following criteria (two or more of the following):

  • Temperature >38°C or <36°C
  • HR >100 bpm
  • FR >20 respiratory acts/min or PaCO2 <32mmHg
  • GB >14 x 109/dL or <4 x 109/dL
  • EGA: lactates >2mmol/L (or 18 mg/dL)
  • PCR >2DS from normal value
  • Procalcitonin >2DS from normal value or positive laboratory culture result for the presence of bacteria (urinoculture, peritoneal fluid culture, abscess...).
  • obtaining informed consent
  • Women who have had at least one ultrasound (transabdominal and/or transvaginal) and one CT scan for suspected postpartum infection

Exclusion criteria

  • Women with localized or systemic infection following infection unrelated to delivery or incision site (in case of cesarean section), such as pneumonia, mastitis, influenza, COVID-19.

Treatment and study plan

Primary outcomes

  1. Presence of ultrasound signs of infection on ultrasonography

    Time frame: Within 90 days after delivery

    Presence of a hypoanechogenic area at the fascial level or hyperechogenic echoes at the level of the endometrial cavity. Ultrasound signs will be compared with CT scans of patients with established postpartum infection. CT scans are currently the gold standard for the diagnosis of infection, and investigators will rely on what is in the report in the medical record.

Study contacts

Contact information is provided by the study sponsor or research team.

Elena Brunelli, MD

CONTACT

[email protected]

05121414379

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 6, 2025
Registry last updated
Jan 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.